We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-14.95%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.72B
AUM Growth
-$950M
Cap. Flow
-$368M
Cap. Flow %
-21.39%
Top 10 Hldgs %
48.56%
Holding
373
New
67
Increased
88
Reduced
111
Closed
78

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$59.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$32.9M
3
AMGN icon
Amgen
AMGN
+$18M
4
LLY icon
Eli Lilly
LLY
+$15.9M
5
BMY icon
Bristol-Myers Squibb
BMY
+$7.23M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$6.04M
2
ABT icon
Abbott
ABT
+$4.77M
3
RGNX icon
Regenxbio
RGNX
+$4.1M
4
CELG
Celgene Corp
CELG
+$3.94M
5
UTHR icon
United Therapeutics
UTHR
+$3.59M

Sector Composition

Rank Sector Weight
1 Healthcare 17.88%
2 Financials 0.23%
3 Consumer Staples 0.05%
4 Technology 0.03%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONCS
126
DELISTED
OncoSec Medical Incorporated
ONCS
$1.44M 0.08%
5,336
+1,545
+41% +$530K
CSCI
127
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
$1.44M 0.08%
4,006
+3,336
+498% +$1.24M
SRRA
128
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$1.4M 0.08%
23,521
+6,328
+37% +$395K
SPHS
129
DELISTED
Sophiris Bio, Inc.
SPHS
$1.39M 0.08%
496,729
-260,304
-34% -$737K
OPK icon
130
CALL
Opko Health
OPK
$1.06B
$1.39M 0.08%
1,491
-1,000
-40% -$10.3K
MBAI
131
Check-Cap
MBAI
$7.81M
$1.35M 0.08%
2,396
-44
-2% -$23.5K
KITE
132
PUT
DELISTED
Kite Pharma, Inc.
KITE
$1.3M 0.08%
291
-886
-75% -$43.5K
SIOX
133
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$1.25M 0.07%
12,625
+986
+8% +$104K
BDSI
134
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$1.22M 0.07%
698,235
+8,335
+1% +$17K
CORV
135
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$1.21M 0.07%
437,720
-46,785
-10% -$134K
NVRO
136
CALL
DELISTED
NEVRO CORP.
NVRO
$1.2M 0.07%
165
+4
+2% +$342
GENE
137
DELISTED
Genetic Technologies Ltd.
GENE
$1.16M 0.07%
+53,517
New +$1.48M
APDNW
138
DELISTED
Applied DNA Sciences Inc Warrant
APDNW
$1.14M 0.07%
+2,277,612
New +$1.81M
IRD
139
Opus Genetics
IRD
$272M
$1.04M 0.06%
15,264
-4,454
-23% -$362K
RXDX
140
DELISTED
Ignyta, Inc.
RXDX
$1.03M 0.06%
195,000
-30,900
-14% -$180K
AGEN
141
PUT
Agenus
AGEN
$272M
$1.03M 0.06%
128
+1
+0.8% +$98
TRAW icon
142
Traws Pharma
TRAW
$7.6M
$1.03M 0.06%
80
+10
+14% +$148K
SCMP
143
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
$1.02M 0.06%
+75,000
New +$1.05M
CAPR icon
144
Capricor Therapeutics
CAPR
$380M
$990K 0.06%
37,205
+1,461
+4% +$43.7K
LRMR icon
145
Larimar Therapeutics
LRMR
$385M
$986K 0.06%
+25,833
New +$1.05M
FOMX
146
CALL
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$978K 0.06%
881
+157
+22% +$1.48K
LXRX icon
147
Lexicon Pharmaceuticals
LXRX
$1.02B
$969K 0.06%
+70,040
New +$1.12M
AIM
148
AIM ImmunoTech
AIM
$6.72M
$960K 0.06%
317
+9
+3% +$36.3K
DRRX
149
CALL
DELISTED
DURECT Corp
DRRX
$928K 0.05%
693
+517
+294% +$6.6K
RCKT icon
150
Rocket Pharmaceuticals
RCKT
$332M
$921K 0.05%
37,733
+1,732
+5% +$49.4K
4 5
6
7 8

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2016 Portfolio in Review

As of Q4 2016, Sabby Management held 373 positions worth $1.72B, down 36% from $2.67B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Sabby Management withdrew a net $368M in Q4 2016, closing 78 positions and reducing 111 holdings. Its most notable exit was Shire pic, an estimated $6.04M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 9.2% a quarter earlier, followed by Financials and Consumer Staples.

Against the trend, Sabby Management opened a new position in Eli Lilly worth $15.7M.

  • Sabby Management's largest Q4 2016 buy was Eli Lilly: 213,113 shares worth $15.7M.
  • Sabby Management added most to Sarepta Therapeutics in Q4 2016, an estimated $59.4M increase.
  • Sabby Management's biggest Q4 2016 reduction was Regenxbio, cutting an estimated $4.1M.
  • Sabby Management fully exited Shire pic in Q4 2016, selling an estimated $6.04M.
  • Sabby Management's ten largest holdings make up 49% of its $1.72B portfolio in Q4 2016.
  • Sabby Management opened 67 new positions and closed 78 in Q4 2016.
  • Sabby Management's portfolio value fell 36% quarter-over-quarter to $1.72B.

Based on Sabby Management's 13F filing for Q4 2016, filed 14 Feb 2017.